This review will examine the main strategies historically adopted to therapeutically target the NF-κB pathway in cancer, illustrating the principal classes of synthetic compounds and natural products that have been developed to inhibit oncogenic NF-κB signalling, and focusing on some of the more promising emerging approaches being developed to overcome the historical limitations of conventional NF-κB-targeting therapeutics. Here, NFKB1 is linked to cancer.